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ARTICLE
The tetraspanin CD9 controls migration and
proliferation of parietal epithelial cells and
glomerular disease progression
Hélène Lazareth1,2,3,4,18, Carole Henique 1,2,5,18, Olivia Lenoir 1,2,18, Victor G. Puelles 6,7,8,18,
Martin Flamant9, Guillaume Bollée1,2, Cécile Fligny1,2, Marine Camus1,2, Lea Guyonnet10, Corinne Millien1,2,
François Gaillard1,2, Anna Chipont1,2, Blaise Robin 1,2, Sylvie Fabrega11, Neeraj Dhaun 12, Eric Camerer 1,2,
Oliver Kretz7,13, Florian Grahammer7,13, Fabian Braun 7,13, Tobias B. Huber7,13, Dominique Nochy14,
Chantal Mandet14, Patrick Bruneval14, Laurent Mesnard15, Eric Thervet1,2,3, Alexandre Karras1,2,3,
François Le Naour16,19, Eric Rubinstein 17,19, Claude Boucheix 17,19, Antigoni Alexandrou4,19,
Marcus J. Moeller6,19, Cédric Bouzigues4 & Pierre-Louis Tharaux 1,2,3
The mechanisms driving the development of extracapillary lesions in focal segmental glo-
merulosclerosis (FSGS) and crescentic glomerulonephritis (CGN) remain poorly understood.
A key question is how parietal epithelial cells (PECs) invade glomerular capillaries, thereby
promoting injury and kidney failure. Here we show that expression of the tetraspanin CD9
increases markedly in PECs in mouse models of CGN and FSGS, and in kidneys from indi-
viduals diagnosed with these diseases. Cd9 gene targeting in PECs prevents glomerular
damage in CGN and FSGS mouse models. Mechanistically, CD9 deﬁciency prevents the
oriented migration of PECs into the glomerular tuft and their acquisition of CD44 and β1
integrin expression. These ﬁndings highlight a critical role for de novo expression of CD9 as a
common pathogenic switch driving the PEC phenotype in CGN and FSGS, while offering a
potential therapeutic avenue to treat these conditions.
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Necrotizing crescentic glomerulonephritis (CGN) and focalsegmental glomerulosclerosis (FSGS) are life-threateningdiseases leading to irreversible renal failure. Over the past
years, increasing evidence supports the notion that glomerular
parietal epithelial cells (PEC) are implicated in the formation of
crescents in CGN and in glomerular scarring during FSGS1–3. In
these two diseases, the common feature is the invasion of the
glomerulus, the blood-ﬁltering unit of the kidney, by PECs
leading to its destruction. However, the mechanisms underlying
the change in PEC phenotype remain unclear, as do those driving
their oriented migration toward the glomerular tuft and their
increased capacity to proliferate and form hypercellular and
sclerotic lesions.
Aiming to identify factors underlying PEC activation, we
revealed increased expression of CD9 using comparative deep
RNA sequencing of mouse and human normal and diseased
glomeruli, conﬁrmed expression by immunohistochemistry, and
investigated roles of this tetraspanin in CGN and FSGS patho-
geny. CD9 has been extensively studied in cancer, where it
facilitates proliferation, migration, adhesion, and survival through
the organization of plasma membrane microdomains4,5. We
hypothesized that CD9 induction in PECs may facilitate paracrine
signaling across the urinary chamber, and thus constitute a
pathogenic switch for glomerular demolition.
Cellular functions of CD9 are directly dependent on its cellular
expression and vary according to its association with other pro-
teins. Due to its speciﬁc structure, CD9 has the ability to interact
with several partners. CD9 has been described to associate with
CD44 and the pre-β1 integrin subunit6,7, the growth factor
heparin-binding EGF-like growth factor (HB-EGF)8, as well as
with epidermal growth factor receptor (EGFR)9 and platelet-
derived growth factor receptor (PDGFR)10. HB-EGF-dependent
EGFR activation and PDGF triggering have been previously
implicated in CGN and membranoproliferative glomerulone-
phritis11–15, although it is unknown if they modulate the PEC
phenotype.
Here, we describe the de novo expression of the tetraspanin
CD9 in PEC during CGN and FSGS in mice and humans. We
decipher its pathogenic role in vivo using mouse models of CGN
and FSGS and show that the speciﬁc deletion of Cd9 in PEC
protects from glomerular damage. In vitro, we show that CD9
deﬁciency impairs the ability of PECs to proliferate and to
migrate toward a steep gradient of chemoattractant in micro-
ﬂuidic channels. We further show that high CD9 expression is
required for full activation of the HB-EGF-EGFR and PDGF-BB-
PDGFR pathways and thus, CD9 lowers threshold for oriented
PEC migration. These ﬁndings reveal that expression of CD9 is a
common pathogenic switch that directly drives glomerular injury
in both CGN and FSGS in humans and mice.
Results
CD9 de novo expression during CGN. In order to identify novel
markers of cells participating to destructive processes in extra-
capillary glomerular diseases, we carried out comparative analyses
of RNA sequencing data from freshly isolated glomeruli from
mice with a time course after nephrotoxic serum (NTS)-induced
CGN at day 4 and day 10 (Fig. 1a). This approach revealed a
striking increase in Cd9 transcript abundance in glomeruli as
proliferative extracapillary diseases progressed (Fig. 1b). Of note,
the relative increase in Cd9 mRNA expression occurred earlier
than the one of Cd44, a known marker of PEC activation2,16–19
with an earlier signiﬁcant rise, suggesting a role for CD9 in dis-
ease initiation.
Immunostaining revealed early de novo expression of CD9 in
PECs and in cells invading the glomerular capillary and devoid of
podocyte markers (Fig. 1c, d). This was further conﬁrmed with
observation that the majority of the CD9-expressing cells
displayed CD44 and PDPN/podoplanin, whereas SNP/synapto-
podin+ cells expressed little or no CD9 (Fig. 1e; Supplementary
Figs 1, 2). Comparative immunohistochemical analysis indicated
that the prevalence of CD9+ cells consistently reﬂects different
degrees of podocyte injury (Fig. 1d).
Immunohistochemistry analyses also supported the relevance
of this ﬁnding to human crescentic glomerulonephritis.
CD9 staining did not reveal glomerular expression in kidney
biopsies from healthy controls or patients with proteinuric non-
proliferative glomerulonephritis, such as minimal change disease
(MCD). Previously reported20–24 constitutive expression was
observed in distal convoluted tubuli, collecting tubuli, and faintly
in mesangial cells and vascular smooth muscle cells (Fig. 1f). In
contrast, intense glomerular CD9 expression was observed in
kidney biopsies from patients diagnosed with human proliferative
glomerulonephritis, such as ANCA-associated nephropathy or
lupus nephritis with CGN, where it was located in PECs as well as
in cells engaged in destructive crescent formation (Fig. 1f).
Cd9−/− mice are protected from CGN and extracapillary
injury. Given the strong association between de novo glomerular
CD9 expression and CGN, we next investigated the role of CD9
during glomerulonephritis in the murine NTS-induced CGN
model. CD9-deﬁcient (Cd9−/−)25 mice showed no renal pheno-
type at baseline. Whereas NTS-challenged Cd9+/+ mice displayed
progressive deterioration of renal function, associating increased
urine albumin-to-creatinine ratio (ACR) with glomerular cres-
centic lesions, CD9 deﬁciency protected mice from glomerular
injury, as shown by a signiﬁcantly ten-times lower ACR (440.6 ±
228.8 mg.mmol−1 in Cd9−/− mice vs. 5204 ± 915.6 mg.mmol−1
in Cd9+/+ mice after 21 days) and ﬁvefold reduction of glo-
merular lesions (4.6 ± 3% vs. 23.9 ± 6.2% of crescents in Cd9−/−
vs. Cd9+/+ mice) (Fig. 2). Strikingly, no Cd9−/− but 7/10 Cd9+/+
mice died from anuric end-stage kidney failure with 30–100% of
crescentic glomeruli. CD9 deﬁciency conferred early protection
with decreased ACR from day 5 onwards.
Platelet and hematopoietic cell CD9 is dispensable for CGN.
The CD9 antigen is strongly expressed on platelets26 and platelets
are activated in CGN, raising the hypothesis of a role for platelet-
borne CD9 in vasculitis-inducing CGN. Therefore, we generated
mice with a speciﬁc deletion of Cd9 in platelets (PF4-Cd9lox/lox
mice) by crossing Cd9-ﬂoxed mice (Supplementary Fig. 3)
with mice expressing CRE selectively in platelets27. PF4-Cd9lox/lox
mice were indiscernible from their control littermates (PF4-
Cd9wt/wt mice) in terms of growth, platelet count, and renal
function until the age of 6 months (Supplementary Fig. 4a–c).
When challenged with the NTN model, platelet-speciﬁc CD9-
deﬁcient mice displayed similar renal injury to control mice, as
measured by ACR, BUN, and crescentic glomerular lesions
(Supplementary Fig. 4b–e).
CD9 was also described originally as a 24-kDa surface protein
of non-T acute lymphoblastic leukemia cells and developing B
lymphocytes28, and in naive T cells29. We thus sought to evaluate
the potential role of non-glomerular CD9 in CGN. Lethally
irradiated Cd9+/+ and Cd9−/− mice were reconstituted with the
bone marrow (BM) from either Cd9+/+ or Cd9−/− congenic
mice. Experimental CGN was induced in the chimeric mice.
Interestingly, only mice with Cd9−/− kidneys were signiﬁcantly
protected from severe glomerular dysfunction and crescentic
demolition, whereas mice with CD9-competent kidneys were not
protected from the development of glomerular lesions with no
inﬂuence of the genotype of their BM cells. Notably, crescentic
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glomerular lesions were more abundant in Cd9+/+ mice than
chimeric Cd9−/− mice with a CD9-competent BM (23.6 ± 3.3%
vs. 8.5 ± 1.9% of crescents) (Supplementary Fig. 5).
These results support the notion that it is the glomerular
expression of CD9 that participates in CGN development and
that crescentic glomerular lesions are not a consequence of CD9
expression in the hematopoietic compartment.
De novo expression of CD9 in PEC promotes glomerular
lesions. As CD9 de novo expression in glomeruli was observed in
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podocytes and PEC in human CGN and, given the recognized
role of podocytes in the progression of crescentic lesions in
CGN2,30–32, we then deleted Cd9 selectively in podocytes (Pod-
Cd9lox/lox mice) by crossing Cd9-ﬂoxed mice with mice expres-
sing CRE under the NPHS2 promoter (Pod-Cre mice)33. Pod-
Cd9lox/lox mice had normal renal function at baseline, and were
indiscernible from their control littermates (Pod-Cd9wt/wt mice)
(Supplementary Fig. 6). In the nephrotoxic nephritis (NTN)
model, Pod-Cd9lox/lox mice had similar renal injury as control
mice, as shown by ACR (807.7 ± 184.2 mg.mmol−1 vs. 864.2 ±
242.3 mg.mmol−1 in Pod-Cd9wt/wt vs. Pod-Cd9lox/lox mice), BUN
(51.96 ± 9.46 mg.dL−1 vs. 49.37 ± 5.01 mg.dL−1 in Pod-Cd9wt/wt
vs. Pod-Cd9lox/lox mice), and crescentic glomerular lesions
(27.67 ± 2.36% vs. 30.00 ± 2.63% of crescents in Pod-Cd9wt/wt vs.
Pod-Cd9lox/lox mice) (Supplementary Fig. 6), thus supporting the
idea that podocyte CD9 expression is not involved in crescent
formation in CGN.
We then generated mice with a speciﬁc Cd9 deletion in PEC
(iPec-Cd9lox/lox mice) by crossing the Cd9-ﬂoxed mice with an
inducible PEC-expressing CRE34. iPec-Cd9lox/lox mice had
normal renal function (BUN= 23.9 ± 1.3 mg.dL−1 vs. 20.7 ± 1.7
mg.dL−1 in iPec-Cd9wt/wt) and no histological abnormalities
neither at a microscopic nor at an ultrastructural level.
Furthermore, glomerular CD9 expression was not detected at
baseline (Supplementary Fig. 7).
During the time course of the NTN model, iPec-Cd9wt/wt
control mice showed a rapid increase in ACR that ﬁnally led to
impaired renal function associated with severe glomerular
Fig. 1 CD9 is overexpressed by glomerular cells during CGN in mice and humans. a Schematic strategy to identify differentially expressed genes overtime
on day 4 and 10 (black arrows), in freshly isolated glomeruli from mice developing CGN upon nephrotoxic serum (NTS) or PBS injection (orange arrows).
At day 4, no crescent has been constituted yet, whereas mice display > 50% of crescentic glomeruli on day 10. b Relative increase in Cd44 mRNA
expression is shown as a control for assessment of PEC “activation” that was detected on day 10 only. Cd9 mRNA expression was signiﬁcantly higher in
glomeruli during NTN on day 4 and 10 as compared with PBS-infused control mice. The data are expressed as mean of FPKM (fragments per kilobase per
million reads mapped) +/− s.e.m of four and seven mice per condition. t test: *P < 0.05; **P < 0.01; ****P < 0.0001 for NTS-injected vs. PBS-injected mice.
c Representative images showing immunohistochemical staining of CD9 (brown) from murine kidney sections in normal conditions (control) and 10 days
after nephrotoxic serum injection (NTN). Scale bar, 50 µm. d Representative images showing immunoﬂuorescent stainings for CD9 (red) and PODXL/
podocalyxin (green) in adult mice at baseline (control) and 10 days after nephrotoxic serum injection (NTN). Nuclei were stained with DAPI (blue). Scale
bar, 50 µm. e Representative images showing immunoﬂuorescent stainings for CD9 (red), CD44 (green), SNP (blue), and DAPI (white) in adult mice at
10 days after nephrotoxic serum injection (NTN). Scale bar, 50 µm. (f Representative images showing immunohistochemical staining of CD9 (brown) from
pathological human kidneys: MCD minimal change disease, ANCA ANCA vasculitis, LN lupus nephritis. Scale bar: 50 µm. Source data are provided as a
Source Data ﬁle
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crescentic lesions (61.2 ± 11.4% vs. 16.9 ± 4.7% of crescents in
iPec-Cd9) (Fig. 3a–d). Conversely, iPec-Cd9lox/lox mice displayed
renal protection as shown by signiﬁcantly lower ACR starting
from day 7 of experimentation, reduced BUN and preserved renal
architecture (Fig. 3a–d). Furthermore, we found CD9 expression
in crescents and along the Bowman’s capsule in control
NTN mice, while efﬁcient deletion of Cd9 was validated in
iPec-Cd9lox/lox mice by no CD9 expression in PEC (Fig. 3e, f).
Furthermore, while typical podocyte-PEC synechiae participating
in crescent formation were observed in iPec-Cd9wt/wt NTN mice,
glomerular ultrastructure was preserved in iPec-Cd9lox/lox NTN
mice (Fig. 3g). Interestingly, CD9-expressing cells were activated
PECs as shown by coexpression of CD9 with the hyaluronan
receptor CD442, whereas no activated PECs were observed
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in iPec-Cd9lox/lox NTN mice (Fig. 3f). Thus, CD9 appears to be
implicated in PECs activation. Altogether, these results indicate
that de novo expression of CD9 in PECs participates in the
development of crescents in experimental CGN.
CD9 de novo expression in PEC during human FSGS. Given
the coexpression of CD9 with the activated-PEC marker CD44
during proliferative glomerulonephritis, we next investigated
whether CD9 was involved in other diseases with PEC phenotypic
changes, like FSGS35,36. Interestingly, CD9 was also de novo
expressed in glomeruli during human FSGS, including with the
collapsing variant, where strong staining was found at synechiae
and along the Bowman’s capsule (Fig. 4a). These observations
suggest that CD9 could be involved not only in CGN progression
but also in other non-proliferative glomerulopathies.
CD9 deﬁciency in PEC reduces the development of FSGS. We
then challenged PEC-speciﬁc CD9-deﬁcient mice with a model of
FSGS that combines high-salt diet and deoxycorticosterone
acetate (DOCA) with unilateral nephrectomy. Unine-
phrectomized mice implanted with placebo pellets were used as
controls. In placebo-treated wild-type mice and in iPec-Cd9lox/lox
DOCA mice, CD9 was not detected in glomeruli, thus conﬁrming
that CD9 is not expressed in PEC at baseline (even after unine-
phrectomy) and that efﬁcient deletion in iPec-Cd9lox/lox mice was
obtained (Fig. 4b). Conversely, in iPec-Cd9wt/wt DOCA mice,
strong de novo glomerular expression of CD9 was observed, and
co-staining with CD44 demonstrated that CD9-expressing cells
were activated PEC (Fig. 4b). Vehicle-treated mice did not display
renal dysfunction or histological abnormalities (Fig. 4; Supple-
mentary Fig. 8). This supports the hypothesis that de novo CD9
expression is concomitant with PEC activation during FSGS.
While iPec-Cd9wt/wt DOCA-salt-treated mice showed a pro-
gressive increase in ACR (164.8 ± 71.1 mg.mmol−1 at W5 of the
experiment) and BUN (25.3 ± 1.2 mg.dL) associated with glo-
merular sclerosis and FSGS lesions in iPec-Cd9wt/wt mice (per-
centage of glomeruli with > 50% sclerosis, 42 ± 4% and percentage
of FSGS lesions, 16.9 ± 2.6% after 6 weeks of the experiment),
PEC-speciﬁc CD9 deﬁciency was associated with a signiﬁcant
reduction in these parameters (ACR 86.6 ± 27.3 mg.mmol−1 at
W5 of the experiment, BUN 17.6 ± 1.1 mg.dL−1, percentage of
glomeruli with > 50% sclerosis 14.3 ± 2.3% and percentage of
FSGS lesions 7.4 ± 2.6% in iPec-Cd9lox/lox DOCA mice at W6)
(Fig. 4c–h). Not only were CD44-positive PEC observed in
higher numbers in iPec-Cd9wt/wt DOCA mice, but the number of
CD44+ PEC also strongly correlated with the number of
abnormal glomeruli (R= 0.89) and glomerulosclerosis (R= 0.90)
(Fig. 4i–k). CD44+ PEC surrounding the Bowman’s capsule were
identiﬁed in FSGS lesions by immunoﬂuorescence (Supplemen-
tary Fig. 8a). Podocyte loss was greater in iPec-Cd9wt/wt DOCA
mice as shown by P57 and WT1 staining and correlated with PEC
activation. Podocyte volume was increased in DOCA mice with
no inﬂuence of genotype supporting the idea that the capacity of
podocytes to respond to hypertrophic stress was maintained in
the absence of CD9 (Supplementary Fig. 8a–g). Glomerular
ultrastructure was preserved in iPec-Cd9lox/lox DOCA mice,
whereas iPec-Cd9wt/wt DOCA mice exhibited large ﬁbrous
depositions in the glomerular basement membrane and ﬂocculo-
capsular synechiae (Supplementary Fig. 8h). Importantly, the
differences observed between iPec-Cd9lox/lox and iPec-Cd9wt/wt
mice were not related to blood pressure differences, as both
genotypes demonstrated similar blood pressure increase in
the time course of the DOCA-salt model (systolic blood pres-
sure 150.6 ± 4.8 vs. 154.9 ± 4.6 mmHg in iPec-Cd9wt/wt vs.
iPec-Cd9lox/lox DOCA mice) (Supplementary Fig. 9a). Hemody-
namic changes cannot explain the differences in podocyte loss
between iPec-Cd9wt/wt and iPec-Cd9lox/lox DOCA mice either, as
glomerular volume remained unchanged between DOCA groups
(8.6 ± 0.7 × 105 vs. 8.1 ± 0.7 × 105 µm3 in iPec-Cd9wt/wt vs. iPec-
Cd9lox/lox DOCA mice; Supplementary Fig. 9b). Interestingly,
interstitial ﬁbrosis was signiﬁcantly reduced in iPec-Cd9lox/lox
DOCA mice supporting the idea that Cd9-speciﬁc deletion in
PEC not only inﬂuences glomerular damage but also tubulo-
interstitial ﬁbrosis and thus global kidney fate (Supplementary
Fig. 9c, d). Collectively, these results support the notion that CD9
is critically involved in the development of glomerular lesions in
experimental FSGS.
We thus demonstrate that CD9 correlates with PEC activation
in both experimental CGN and FSGS and is required for such
phenotypic switch.
We next focused on the underlying mechanisms of Cd9-related
PEC activation using an in vitro approach.
CD9 knockdown prevents PEC proliferation and migration.
Short-hairpin RNA interference yielded a 85% reduction in CD9
expression in a PEC cell line37 (Supplementary Fig. 10a, b). CD9-
depleted PECs displayed a strong delay in adhesion to plastic
(Fig. 4a) that was associated with reduced cell spreading (3012 ±
135.7 vs. 1649 ± 70.7 µm2 for scramble and Cd9 shRNA PEC,
respectively; Supplementary Fig. 10c, d). This change of pheno-
type was not a consequence of increased apoptosis, as measured
by caspase 3-cleavage and propidium iodide/annexin-V ﬂow
cytometry (Supplementary Fig. 10e–g).
PDGF-BB stimulation induced PEC proliferation as measured
by an increased number of KI67+ cells. Cd9 knockdown reduced
the number of KI67+ cells (Fig. 5b; Supplementary Fig. 10h),
suggesting that CD9 controls PDGF-BB-mediated PEC prolifera-
tion. Next, we quantiﬁed in vivo PEC proliferation (PCNA+
PECs) using both NTN and DOCA-salt models in iPec-Cd9wt/wt
mice. As expected, extracapillary cell proliferation was measured
in diseased iPec-Cd9wt/wt animals, while PEC proliferation was
abolished in iPec-Cd9lox/lox mice (Supplementary Fig. 11).
Fig. 3 PEC-selective Cd9 deletion protects mice from nephrotoxic serum-induced CGN. a Urine albumin-to-creatinine ratio in iPec-Cd9wt/wt and iPec-
Cd9lox/lox mice at baseline and from day (D) 4 to day 21 during NTN model. The data represent mean +/− s.e.m. of n= 14 and 15 mice per group.
Individual values are shown in dots. t test: *P < 0.05 and **P < 0.01 iPec-Cd9wt/wt vs. iPec-Cd9lox/lox mice. b Blood urea nitrogen (BUN) levels in iPec-
Cd9wt/wt and iPec-Cd9lox/lox mice after 21 days of the NTN model. The data represent mean +/− s.e.m. of n= 14 and 15 mice per group. Individual
values are shown in dots. t test: ***P < 0.001. c Representative images showing Masson’s trichrome staining of kidney sections in iPec-Cd9wt/wt and
iPec-Cd9lox/lox mice after 21 days of the NTN model. iPec-Cd9wt/wt mice display ﬁbrinoid necrosis (white star) and crescent (arrow). Scale bar, 50 µm.
d Associated quantiﬁcation of the percentage of glomeruli with crescents. The data represent mean +/− s.e.m. of n= 8 mice per group. Individual values
are shown in dots. t test: **P < 0.01. e–g Representative images showing immunoﬂuorescent stainings of (e) CD9 (red) and PODXL/podocalyxin (green)
and (f) CD9 (red) and CD44 (green), on kidney sections from iPec Cd9wt/wt and iPec Cd9lox/lox mice after 21 days of the NTN model. Nuclei were stained
with DAPI. Scale bar, 50 µm. f Representative images of transmission electron microscopy in iPec-Cd9wt/wt and iPec-Cd9lox/lox mice after 21 days of the
NTN model. Arrows indicate parietal epithelial cells, * stand for podocytes and an # shows ﬁbrinoid deposits. Scale bar: 2 µm. Source data are provided as a
Source Data ﬁle
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Together, these ﬁndings suggest that CD9 de novo expression
may be an important mediator of PECs proliferation in FSGS and
CGN.
Importantly, HB-EGF and PDGF-BB both induced PEC
migration in scratch assays. Cd9 knockdown reduced migration
in response to both growth factors (Fig. 5c, d; Supplementary
Movies 1–6).
PEC sensing of local chemoattractants involves CD9. As
observed in CGN and FSGS, PECs attach to and migrate toward
the glomerular tuft. This led us to hypothesize that they may be
sensitive to chemoattractants ﬁltered through the capillary and/or
locally produced by it.
Therefore, we modeled a growth factor steep gradient in
microﬂuidic channels to evaluate the capability of PECs to sense
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local changes in chemoattractants that may surround them in the
urinary chamber.
We used microﬂuidic microchannels to assess the oriented
migration of PECs in a PDGF-BB gradient (Fig. 5e–g). The T-
shape of the microﬂuidic microchannel allowed us to apply
PDGF-BB-containing medium at one entrance and standard
medium at the other, thus creating a PDGF-BB concentration
gradient in the principal branch of the channel. The shape and
the values of the gradient could be calculated at every position (y
axis, Fig. 5g). The absolute value of the average cell displacement
was similar between scramble and Cd9 shRNA PECs (Fig. 5h),
suggesting that the ability to migrate was preserved despite
defects in adhesion and spreading observed under static
conditions. PECs showed limited motion with the direction ﬂow,
and instead chose to migrate orthogonally to the ﬂow attracted by
the PDGF-BB gradient. No migration or enhancement of motility
were observed in regions of the microchannels where the average
PDGF concentration is signiﬁcantly higher (Supplementary
Fig. 12), suggesting that the effect of CD9 knockdown cannot
be compensated by signiﬁcant PDGFR overstimulation. Strik-
ingly, CD9 depletion abolished the ability of PECs to respond to
the gradient (Fig. 5i). Altogether, these experiments indicate that
Cd9 knockdown in PECs impairs their gradient-sensing ability
without affecting their motility.
CD9-deﬁcient PECs display reduced expression of β1 integrin.
Given the role of ITGB1 in cell spreading and migration38–40 and
the fact that CD9 has been found to associate with the pre-β1
subunit of ITGB1 in other cell types41, we then analyzed ITGB1
expression in CD9-depleted PECs. Knocking down Cd9 in PECs
resulted in an ∼30% reduction in ITGB1 content in cell lysates
(Fig. 6a, b), while immunoﬂuorescence conﬁrmed loss of ITGB1
membrane expression in CD9-deﬁcient PECs (Supplementary
Fig. 13a). Not only Itgb1 but also Itgb3, Itga1, Itga3, and Itga10
mRNA expression were decreased in CD9-deﬁcient PECs, thus
suggesting involvement in altered cytoskeletal dynamics in these
cells (Supplementary Fig. 13b). In situ, basal ITGB1 expression
was low with a mesangial and endothelial endocapillary pattern
(Supplementary Fig. 14). ITGB1 expression was enhanced in
iPEc-Cd9wt/wt diseased glomeruli in both experimental CGN and
FSGS and localized to crescents and activated PECs. Interestingly,
expansion of the ITGB1 expressing cells correlated with loss of
podocyte marker NPHS2 (Supplementary Fig. 14) and colocalized
with PEC activation marker CD44 to a large extent, but displayed
a more widespread expression (Supplementary Fig. 15).
In iPec-Cd9lox/lox NTN and iPec-Cd9lox/lox DOCA mice,
ITGB1 expression was low in PEC (Fig. 6c; Supplementary
Fig. 14). These results suggest that ITGB1 is a novel marker of
PEC activation and might participate in glomerular extracapillary
lesions formation.
Podocyte loss is not sufﬁcient to trigger CD9 expression in
PECs and FSGS. It has been believed that podocyte injury may
occur prior to the PEC activation. Therefore, we evaluated whe-
ther podocyte injury would induce CD9 expression in PECs. To
this end, we assessed CD9 glomerular expression in a model
characterized with accentuated podocyte loss and glomerulo-
sclerosis upon genetic targeting of podocyte autophagy that
exacerbates diabetic nephropathy. In that model, we demon-
strated increased proteinuria and podocyte injury with foot
process effacement and loss of differentiation markers in Nphs2.
cre Atg5 lox/lox diabetic mice, but never observed FSGS
nor synechiae 42. We re-analyzed these kidneys looking for
the PEC activation marker CD44 and for CD9 expression. We
found no CD44 and no CD9 expression in PECs, neither in
diabetic WT nor in diabetic Nphs2.cre Atg5lox/lox mice (Supple-
mentary Fig. 16), despite the latter group showed marked
podocyte loss. Thus, in this speciﬁc case, podocyte injury is not
sufﬁcient to induce neither PEC activation nor CD9 de novo
expression.
Conversely, we recently observed experimental FSGS without
primary podocyte insult but with manipulation of the endothelial
HIF2/EPAS1 pathway using mouse genetics 43. Upon chronic
angiotensin II infusion and high salt diet, Cdh5-CRE Epas1lox/lox
mice developed similar degree of podocyte injury to their wild-
type counterparts. Surprisingly, FSGS lesions with CD44+ and
ﬁbronectin+ PECs were observed only in Cdh5-CRE Epas1lox/lox
hypertensive mice 43. We next analyzed CD9 expression and
found de novo CD9 expression in PECs in the hypertensive
Cdh5-CRE Epas1lox/lox mice only. De novo high CD9 expression
was almost exclusively associated with FSGS lesions and CD44
expression as shown in Supplementary Fig. 16. Altogether, these
ﬁndings suggest that endothelial derived mediators may con-
tribute to CD9 induction in PECs and FSGS.
PDGFR and EGFR pathways are impaired in Cd9-deﬁcient
PEC. PDGF-BB-mediated cell migration involves signal trans-
duction through PDGFRβ phosphorylation, notably at Tyr
100944, and subsequent FAK activation. Interestingly, Cd9-
depleted PECs showed decreased abundance of PDGFRβ both at
protein and mRNA level (Supplementary Fig. 13c). While PDGF-
BB induced a rapid and transient PDGFRβ phosphorylation, Cd9-
depleted PECs showed impaired PDGFRβ phosphorylation
(Fig. 6d–f). As a consequence, activation of FAK was also
Fig. 4 Glomerular cells overexpress CD9 during FSGS and PEC-selective Cd9 deletion protects mice from FSGS in the DOCA-salt model. a Representative
images showing immunohistochemical staining of CD9 (brown) from pathological human kidneys: minimal change disease (MCD), primary FSGS,
collapsing FSGS in HIV-associated nephropathy (HIVAN), and collapsing FSGS in IgA nephropathy (IgAN). Scale bar, 50 µm. b Representative
images showing immunoﬂuorescent stainings of CD9 (red), PODXL/podocalyxin (green), and DAPI (blue) on kidney sections from iPec-Cd9wt/wt
and iPec-Cd9lox/lox mice at week 6 of the DOCA-salt model. Scale bar, 50 µm. c Urine albumin-to-creatinine ratio and (d) BUN in iPec-Cd9 mice
during the DOCA-salt model (n= 5 mice in placebo groups, n= 10 mice in DOCA groups); ANOVA: *P < 0.05, ***P < 0.001, and ****P < 0.0001
between iPec-Cd9wt/wt and iPec-Cd9lox/lox mice in the DOCA-salt model; ##P < 0.01 between W2 and W6 of DOCA treatment in iPec-Cd9wt/wt group.
e, f Representative images showing Masson’s trichrome (e) and periodic-acid Shiff (f) staining on kidney sections from iPec-Cd9wt/wt and iPec-Cd9lox/lox
mice after 6 weeks of DOCA. Scale bar, 50 µm. g, h Associated quantiﬁcation of the percentage of glomeruli (g) with more than 50% of sclerosis
and (h) with FSGS lesions (n= 5 and 8 mice, respectively, in placebo and DOCA groups). *iPec-Cd9wt/wt vs. iPec-Cd9lox/lox mice in the DOCA
groups; #iPec-Cd9wt/wt placebo-treated vs. DOCA-treated; ANOVA: *P < 0.05, ##P < 0.01, ***P < 0.001. i Quantiﬁcation of the percentage of glomeruli
with CD44-positive PEC at W2 and W6 in iPec-Cd9wt/wt and iPec-Cd9lox/lox mice (n= 4 and 8 mice, respectively, in placebo and DOCA groups).
*iPec-Cd9wt/wt vs. iPec-Cd9lox/lox mice in the DOCA groups; #iPec-Cd9wt/wt placebo-treated vs. DOCA-treated; $iPec-Cd9lox/lox placebo-treated vs.
DOCA-treated. ANOVA: $$$P < 0.001, **** and ####P < 0.0001. j, k Correlation between the percentage of CD44-positive PEC and the percentage of
abnormal glomeruli (j) or glomerulosclerosis score (k) in all mice. Source data are provided as a Source Data ﬁle
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impaired, as shown by reduced phosphorylation at Tyr 397
(Fig. 6d, g). In a similar manner, we observed that the HB-EGF/
EGFR/FAK pathway was also defective in CD9-depleted cells with
a decreased level of total EGFR and its Tyr 1068 phosphorylation
after HB-EGF stimulation. Consistently, FAK phosphorylation
was reduced as well (Fig. 6h–k; Supplementary Fig. 13c). These
results suggest that the impaired migratory capacity observed in
Cd9-depleted PECs is a consequence of defective PDGFRβ and
EGFR signaling. Indeed, the lack of gradient-sensing ability
(chemotaxis) of CD9-depleted PECs cannot be explained by the
observed decrease in ITGB1 levels only, as cell motility is
preserved.
CD9 expression in humans correlates with CD44 and ITGB1.
As we observed that CD9 expression in PEC correlated with PEC
activation in experimental CGN and FSGS, and that CD9
depletion was associated with decreased ITGB1 levels, we ana-
lyzed CD9 expression in combination with CD44 and ITGB1 in
human glomerulopathies. Patient characteristics are displayed in
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Supplementary Tables 1 and 2. We found that CD9 closely
colocalized with ITGB1 during human extracapillary glomer-
ulopathies such as ANCA-associated CGN and FSGS, but not in
non-proliferative glomerulonephritides or in normal kidney
(Fig. 7). Notably, CD9 and ITGB1 are predominantly expressed
by PECs along the Bowman’s capsule in FSGS lesions and in
crescents. CD9-CD44 co-staining further conﬁrmed that acti-
vated PECs account for a large number of CD9-expressing cells.
These data support the hypothesis that de novo CD9 expression
in CGN and FSGS contributes to the formation of glomerular
lesions (i.e. crescent formation or synechiae) through PEC
migration/activation, involving HB-EGF-EGFR and PDGFR
pathway activation, and increased ITGB1 levels.
Discussion
Here, we report that pathogenic expression of CD9 by glomerular
parietal epithelial cells drives glomerular damage during CGN
and FSGS. This tetraspanin has emerged as a threshold deter-
minant from our search of systematic clusters of epithelial cell
surface components capable of transducing migratory and pro-
liferative signals in epithelial cells.
Although PECs have been implicated in the generation of
ﬁbrotic lesions in FSGS45 and in the formation of the crescent in
CGN34, we provide evidences that PEC protein is directly
implicated in their activation and pathogenic transformation of
glomerular structure and function. Using genetic tracing of glo-
merular epithelial cells, Smeets et al. previously showed that PEC
accounts for the largest number of cells in the formation of the
crescent during CGN and FSGS in mice2. Here, we show that
CD9 is de novo expressed in PECs among renal pathologies
involving PEC activation (i.e migration and proliferation).
Interestingly, CD9 expression in PECs was found in FSGS-like
(DOCA-salt and angiotensin II-induced hypertension in a sen-
sitive genetic model43) and CGN-like rodent models, always in
association with CD44 expression. Conversely, no CD9 expres-
sion was found in PECs in mouse model of diabetic nephropathy,
even in a model prone to podocyte injury (i.e. Nphs2.cre Atg5lox/
lox). Thus, CD9 seems to be a novel and selective driver of PEC
activation.
Furthermore, we demonstrate that a speciﬁc ablation of CD9
expression in PECs confers protection not only in the inﬂam-
matory model of CGN but also in a model of FSGS, a more
chronic form of glomerular injury.
Podocyte injury is critical for destruction of the ﬁltration
barrier in glomerulonephritis. Silencing Cd9 not only reduced
PEC-induced glomerulosclerosis but also maintained the number
of podocytes. While CD9 is expressed by both podocytes and
PECs in human pathologies, CD9 de novo expression in
podocytes in NTN and DOCA-salt models was low, probably
explaining why Cd9 deletion in podocytes had no impact on
outcomes.
This supports the notion that podocyte displacement by
invading PECs contributes to the destruction of the glomerular
ﬁltration barrier in FSGS. Triggers for CD9 overexpression are
unknown. CD9 was found to be upregulated by mechanical stress
in cultured immortalized podocytes whereas most of the tetra-
spanins remained unaffected46. Thus, further work would be
useful to ascertain the inﬂuence of mechanical stimuli in CD9
regulation in PECs.
Changes in the PEC phenotype, i.e. the proliferation and
migration of a normally quiescent cell population, represent key
steps in the destruction of glomeruli during CGN and FSGS1,34,45.
It has been previously shown that CD9 can either promote or
suppress cancer cell migration and metastasis, depending on the
type of cancer, the type of cells involved, and the migratory sig-
nal47,48. Meanwhile the case of many types of cancer cells, where
CD9 promotes cell proliferation and migration49–51, may share
similarities with the mechanisms, whereby CD9 drives renal
disease via aberrant expression in PECs. Targeting CD9 with
speciﬁc antibodies can reduce the migration of malignant cancer
cells52. Concordantly, Cd9 silencing in immortalized PECs
impaired their ability to proliferate and migrate in a directional
manner. These ﬁndings should help decipher the origins of glo-
merular injury. Interestingly, CD9 induces a complete remodeling
of PECs and seems to drive an EMT-like phenotype as shown by
changes in Cldn1, Vimentin, or Snail in CD9-deﬁcient PECs.
How does CD9 expression help drive PEC out of quiescence?
HB-EGF activation of EGFR is a key driver of renal damage in
early stages of mouse and human glomerulonephritis11, and CD9
is known to form molecular microdomains at the cell surface in
which EGFR is associated9 and modulate its activation by yet
unknown mechanisms. After paracrine activation of the EGFR
pathway by TGFα, CD9 potentiates EGFR signaling53, although
we previously ruled out the involvement of TGFα in CGN11.
Interestingly, CD9 was shown to be a « diphtheria toxin receptor-
associated protein » (DRAP27), forming a complex with proHB-
EGF at the cell membrane, and upregulating its juxtacrine
mitogenic activity54. Although this could likely play a pathogenic
role, we suspect that other complex mechanisms are at play to
explain the powerful effect of CD9 deﬁciency in vivo and in vitro
in the presence of soluble chemoattractants such as mature HB-
EGF and PDGFBB.
The PDGFR pathway also contributes to renal damage during
CGN. Upregulation or de novo expression of PDGF-BB has been
described in mesangial cells, podocyte vascular cells, tubular and
interstitial cells in animal models, and human renal diseases in
Fig. 5 In vitro CD9 depletion alters adherence, proliferation, and migration in PEC. a Percentage of adherent cells from 30min (30’) to 24 h in PEC
transduced with a Cd9 shRNA-coding lentivirus or a scramble shRNA-coding lentivirus. The data are shown as the mean +/− s.e.m. of n= 25–40 wells per
condition. t test: **P < 0.01, ***P < 0.0001. b Cell proliferation of control PEC (scramble shRNA) and CD9-depleted PEC (Cd9 shRNA) assessed by ﬂow-
cytometry measurement of the percentage of KI67 positive cells under basal conditions and after PDGF-BB stimulation. t test: $ scramble shRNA vs.
scramble shRNA with PDGF-BB, $P > 0.05; #Cd9 shRNA in basal condition vs. scramble shRNA after PDGF-BB stimulation, ##P < 0.01; *scramble shRNA
vs. Cd9 shRNA after PDGF-BB stimulation, *P < 0.05. The data are shown as the mean +/− s.e.m., and individual values are shown in dots (n= 6 and 12
wells per condition). c Migration chambers showing area of migration of scramble shRNA and Cd9 shRNA PEC in basal conditions (control) or after
stimulation by HB-EGF or PDGF-BB during 9 h. d Quantiﬁcation of the area of migration from t= 0 (100%) to t= 12 h. Two-way ANOVA, ***P < 0.001, Cd9
shRNA (shCD9) compared with scramble shRNA (shSCR) under stimulation with HB-EGF or with PDGF. The data are shown as the mean +/− s.e.m. of n
= 4 chambers per condition. e Picture of a microﬂuidic device. f Shape of the gradient in the microchannel. Concentration (C(Y)) at different coordinates of
Y are depicted. g Schematic representation of T-shape microﬂuidic channel showing two entrances perfused either with the PDGF-BB or standard HBSS
medium. h, i Quantiﬁcation of (h) the oriented migration and (i) of the absolute displacement, of control (scramble shRNA) and CD9-depleted (Cd9
shRNA) PEC after stimulation with a gradient of PDGF-BB (20 ng/mL during 3 h). t test: ##P < 0.01 between X (displacement in the ﬂow) and Y
(displacement in the gradient) in basal PEC; **P < 0.01 between scramble shRNA and Cd9 shRNA in Y. The data are shown as the mean +/− s.e.m. of n >
30 cells in 3 or 4 T-shape microﬂuidic channel per condition. Source data are provided as a Source Data ﬁle
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many studies55. The PDGFR has also been reported to associate
with CD910, and PDGFRβ levels and activation were indeed
reduced upon CD9 depletion. Potentiation of EGFR and PDGFR
pathways would be predicted to enable chemotaxis by increasing
engagement of downstream effectors, such as FAK. Various RTKs
are recruited to and enriched within speciﬁc plasma membrane
microdomains56, and CD9 tetraspanin-enriched microdomains
may control actin-dependent protrusive membrane micro-
domains, such as dorsal rufﬂes and invadosomes. CD9 may thus
promote growth factor signaling through the formation and
stabilization of tetraspanin-enriched signaling microdomains57
that promote EGFR and PDGFRβ receptor insertion in the
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plasma cell membrane. Its facilitating role upstream of both
HBEGF-EGFR and PDGFR pathways could position CD9 as an
attractive therapeutic target for both CGN and FSGS.
Another relevant mechanism of action of CD9 could be
through modulation of integrin signaling. In cells that have an
abundant pool of intracellular integrins, CD9 (but not CD81 or
CD82) is associated with the pre-β1 subunit and calnexin, an ER
chaperone protein41. Whether or not these early associations with
tetraspanins are required for proper biogenesis or turnover of the
integrin remains to be determined. This is suggested by the
decrease in ITGB1 protein abundance in Cd9-deleted PEC that
could in turn contribute to their lack of adhesion and motility.
The report of a CD9 conformation-dependent epitope whose
expression depends on changes in the activation state of asso-
ciated α6β1 integrin suggests another potential level of func-
tionally relevant CD9 involvement in β1 integrin-dependent
cellular processes58.
Reduced ITGB1 expression could also participate in the
decrease of PEC proliferation as integrin-mediated extracellular-
matrix attachment is crucial to ensure glomerular epithelial cells
response to growth factors59. Increased expression of both β1 and
β3 integrins have been reported in human CGN60,61. In rodent
models, β1 integrin is overexpressed 7 days after CGN induction,
promoting cell adhesion to the matrix proteins62. Recently, Pra-
koura et al. described the colocalization of NF-κB-induced peri-
ostin with β3 integrin in activated crescentic PEC in the NTN
model61. As a major laminin and collagen receptor, integrin β1
promotes glomerulosclerosis during FSGS by driving collagen
production63. Integrin-linked kinase, which interacts with β1
integrins, is overexpressed by PGP.5-positive cells (PGP.5 being a
PEC marker) in the crescent during rat CGN64.
CD44 has been found recently to participate in PECs pro-
liferation in experimental CGN and FSGS18. Thus, CD9 is a
major regulator of PEC activation also through control of CD44
expression as CD9-deﬁcient PECs presented decreased Cd44
mRNA expression (Supplementary Fig. 13c) and more specta-
cularly, no induction of CD44 high expression upon NTS or
DOCA-salt UNx challenge (Figs 3, 4).
Key observations in rodent models could be reproduced in
human glomerulopathies, suggesting a role for CD9 also in
human disease. Indeed, during human CGN and FSGS, we
showed that activated PEC expressed CD9 that colocalized closely
with ITGB1 and CD44, especially in crescents and synechiae
across the urinary chamber. Interestingly, occurrence of com-
bined expression of CD9 with ITGB1 was more consistent than
combined expression of CD9 with CD44, suggesting the existence
of various stages of PEC activation or distinct subsets of such
cells. Altogether, our results support the implication of CD9 in
PEC activation and ITGB1-mediated glomerular lesions in both
diseases. Although we demonstrate that a clear interaction
exists between CD9, ITGB1, and EGFR/PDGFR, the precise
way by which these proteins interact to regulate adhesion and
chemotaxis is complex, possibly multifactorial and requires fur-
ther investigations.
At last, we observed that PDGF-BB and HB-EGF that are
produced by the glomerular tuft in CGN, and to a lesser although
signiﬁcant extent in FSGS, display chemotactic and mitogenic
inﬂuences on PECs. Modeling urinary gradients of PDGF-BB or
HB-EGF in microﬂuidic channels demonstrated the capability of
PECs to sense local changes in chemoattractants in the urinary
chamber and revealed a critical facilitating role for CD9 in this
process. Extension of such proof-of-concept experiments should
help identifying other key molecules emanating from the injured
capillary and triggering PEC-mediated maladaptive response to
injury.
In conclusion, we demonstrate that preventing local expression
of CD9 by PEC in glomeruli alleviates glomerular damages in two
distinct severe diseases, CGN and FSGS (Supplementary Fig. 17).
Targeting the CD9 pathway could offer therapeutic options and
warrants further attention. CD9 expression in PECs could also
provide a marker for diagnosis of CGN and FSGS. Indeed, CD9-
positive PECs involved in crescent and sclerotic lesions were not
always CD44 positive, implying that markers of PEC activation
may vary as a function of time or reﬂect heterogeneous PEC
subsets. Thus, CD9 staining may be considered for early diagnosis
and management of these diseases.
Finally, our study suggests a concept in which severe kidney
diseases characterized by pathogenic PEC recruitment to the
glomerular tuft may all depend on a CD9-dependent molecular
complex that adjusts the threshold for proliferation and direc-
tional migration of these cells.
Methods
Animals. Mice with a constitutive CD9 deﬁciency have been previously descri-
bed25. For the generation of Cd9-ﬂoxed mice, we inserted on the PTV-0 vector with
a ﬂoxed Neor gene (i) 3′ to the Neor gene a 9 -kb genomic fragment containing Cd9
exon 1 (starting at bp -1625 from the ATG site) and a lox site introduced at the ﬁrst
NheI site of Cd9 intron 1 (3.6 kb 3′ from the start of the 9- kb fragment); and (ii) 5′
to the Neor gene a short arm of 787 bp. The recombination was performed in E14
ES cells (Supplementary Fig. 3). One of the selected ES clones, RH289, was
transfected with the expression vector pIC-Cre65 to remove the Neor gene. The
screening of recombinant ES clones was performed by PCR, and the recombination
was checked by southern blot. E14 Clone RH289-140 harboring the expected
recombination was used for injection into 3.5-day-old C57BL/6 blastocysts, which
were transferred into foster mothers. Chimeric males were crossed with C57Bl/6
females, and heterozygous mice were intercrossed to check for normal CD9
expression of homozygous mice. Heterozygous ﬂoxed mice were backcrossed 15
times on a C57Bl/6J background. Primers used for genotyping the ﬂoxed Cd9 gene
and the ﬂoxed deleted gene (Cd9-fdel) are: UP1 5′-TGCAGGCATGGAGGCGCA
GC-3′, LO1 5′-GTGCCGGCCTCGCCTTTCCC-3′, mCd9 5′-CTGGTCACACCCC
CTAACGGAGC-3′, NL1 5′-CCTACATCTCCCATCTGCCCCCCAT-3′, NL2 5′-C
ATGGAGCTTGGGGAGGCCTTTGGA-3′. CRE recombination deletes the same
genomic fragment than the constitutive Cd9 gene deletion previously reported and
completely suppressed CD9 expression25 (Supplementary Fig. 3).
Mice with a speciﬁc deletion of Cd9 in platelets (PF4-Cre-Cd9) were
generated by crossing homozygous Cd9 ﬂox/ﬂox mice with PF4-Cre mice27. Mice
with a podocyte-speciﬁc deletion of Cd9 (Pod-Cd9) were generated by using
Nphs2-Cre recombinase, which expresses CRE recombinase exclusively in
podocytes33.
Mice with PEC-speciﬁc deletion of Cd9 were generated by crossing iPec-Cre-
positive mice, which expresses CRE recombinase exclusively in PEC after
doxycycline induction, with Cd9-ﬂoxed mice34. iPec-Cre mice were on a mixed
background (C57BL6/J and SV129). Brieﬂy, inducible CRE expression in PEC was
generated by crossing mice with the enhanced reverse tetracycline transactivator
Fig. 6 CD9 depletion alters EGFR- and PDGF-dependent FAK activation and reduced ITGB1 expression. a Western blot analysis of the expression of
ITGB1/β1 integrin in control (scramble shRNA) and CD9-depleted (Cd9 shRNA) PEC and (b) quantiﬁcation. Tubulin was used as a loading control.
c Representative images of immunoﬂuorescent stainings of ITGB1 (red) and PODXL/podocalyxin (green) in glomeruli from iPec-Cd9wt/wt and iPec-Cd9lox/
lox mice after 14 days of the NTN model. Scale bar, 50 µm. Nuclei were stained with DAPI (blue). d Western blot analysis of the expression of phospho-
PDGFR (Y1009), PDGFR, phospho-FAK Y397, and FAK in control (scramble shRNA) and CD9-depleted (Cd9 shRNA) PEC after time sequential stimulation
with PDGF-BB and (e–g) quantiﬁcations. Tubulin was used as a loading control. h Western blot analysis of the expression of phospho-EGFR Y1068, EGFR,
phospho-FAK Y397, and FAK in control (scramble shRNA) and CD9-depleted (Cd9 shRNA) PEC after time sequential stimulation with HB-EGF and (i–k)
quantiﬁcations. Tubulin was used as a loading control. e–g, i–k The data represent mean +/− s.e.m. of n= 4 experiments. *P < 0.05 scramble shRNA vs.
Cd9 shRNA using two-way ANOVA test. Source data are provided as a source data ﬁle
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under the control of the selective PEC promoter (pPEC-rtTA-M2 mice) with mice
expressing CRE recombinase under the control of an inducible promoter
(tetracycline-responsive element). Doxycycline hyclate (Sigma Aldrich) was
administered in drinking water for 14 days (5% sucrose and 1 mg/ml doxycycline)
followed by 1 week of washout.
Age-matched littermates that had no deletion of Cd9 in any cells were
considered as controls. Animals were housed under standard speciﬁc pathogen-free
conditions. All animal procedures were performed in accordance with guidelines of
the European Community (L358–86/609EEC), and were approved by the Institut
National de la Santé et de la Recherche Médicale and the Ministry for Higher
Education and Research (MESR 7646 and TARGET GLOMDIS).
Bone marrow transplantation. Recipient mice were exposed to 9.5 Gy Cesium 137
radiation for 10 min. The day after, each mouse received 10 × 106 bone marrow
cells by intravenous injection (i.v.) under isoﬂurane anesthesia. Mice received
antibiotics treatment (Enroﬂoxacine 0.025%) in drinking water for 2 weeks. Chi-
meric mice were used 6 weeks after transplantation. Transplantation efﬁciency was
determined to be > 90% in parallel experiments.
Induction of nephrotoxic nephritis. Nephrotoxic nephritis was induced on male
mice (10–12 weeks of age) by i.v. of 15 µl of sheep anti-mouse glomerular basement
membrane nephrotoxic serum, which was diluted with 85 µL of sterile PBS. Serum
injections were repeated twice (on days 2 and 3)66. Mice were killed after 21 days.
CD9 CD44 ITGB1 Merge CD9/CD44
Normal
MCD
FSGS
ANCA
ANCA
Fig. 7 In human, CD9 overexpression in pathological glomeruli is associated with CD44 and ITGB1 expression. Representative images of
immunoﬂuorescent stainings of CD9 (left panel), CD44 (second panel), ITGB1/β1 integrin (third panel), and merge for CD9 (red) and CD44 (green)
expression (right panel) on glomeruli from pathological human tissues. Scale bar, 50 µm. Higher magniﬁcations are shown in the insets. MCD minimal
change disease, FSGS focal segmental glomerulosclerosis, ANCA ANCA vasculitis. Source data are provided as a Source Data ﬁle
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11013-2 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:3303 | https://doi.org/10.1038/s41467-019-11013-2 | www.nature.com/naturecommunications 13
DOCA-salt and nephron reduction model. In all, 10-to-15-week-old male mice
underwent unilateral left nephrectomy via ﬂank incision under isoﬂurane anes-
thesia and received 0.1 mg/kg buprenorphine twice daily for 2 days. They were
divided into two groups receiving either deoxycorticosterone acetate (DOCA) or
placebo. DOCA pellets (50 mg of DOCA per pellet) and placebo pellets with 21-day
release (Innovative Research of America) were implanted subcutaneously 2 weeks
after uninephrectomy. A second pellet of DOCA or placebo was implanted 3 weeks
after the ﬁrst implant. All animals received 0.9% NaCl in drinking water ad libitum.
Mice were killed after 6 weeks of DOCA or placebo treatment.
Blood pressure assessment. Blood pressure was measured by using tail cuff
plethysmography with the BP-2000 Blood Pressure Analyzing system (Visitech
system). After a week of habituation, blood pressure was assessed weakly for 2
consecutive days during the entire experiment time course. Values represent the
mean of the two measures.
Biochemical measurements in blood and urine. Urinary creatinine and BUN
concentrations were analyzed by a standard colorimetric method (Olympus
AU400) at the Biochemistry Laboratory of Institut Claude Bernard (IFR2, Faculté
de Médecine Paris Diderot). Urinary albumin excretion was measured by using a
speciﬁc ELISA for quantitative determination of albumin in mouse urine (Cell-
Trend GmbH). Blood count was performed on a Hemavet counter (Drew scien-
tiﬁc) on fresh blood after intracardiac puncture. Heparin was used as anticoagulant.
Transmission electron microscopy procedure. Small pieces of the renal cortex
were ﬁxed in Trump ﬁxative (EMS) and embedded in Araldite M (Sigma Aldrich).
Ultrathin sections were counterstained with uranyl acetate and lead citrate and
then examined in a JEOL 1011 transmission electron microscope with Digital
Micrograph software for acquisition.
Human tissues. Acetic acid-formol-alcohol-ﬁxed, parafﬁn-embedded renal tissue
specimens were obtained from the Pathology department of Hôpital Européen
Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France. Human
tissue was used after informed consent by all the patients and approval form, and
kidney biopsies collection was approved by the Inserm Ethics Committee
(IRB00003888, FWA00005831 NIH OHRP, Ofﬁce of Human Research Protection).
Kidney biopsy specimens were collected in compliance with all relevant ethical
regulations, and those with sufﬁcient tissue for immunohistochemical evaluation
after the completion of diagnosis workup were included.
Histology. Kidneys were immersed in 10% formalin and embedded in parafﬁn.
Sections (4-μm thick) were processed for histopathology or immunohistochem-
istry. Sections were stained with Masson’s trichrome, periodic-acid Schiff or red
Sirius staining. For immunoﬂuorescence, parafﬁn-embedded sections were stained
with the following primary antibodies: rabbit anti-WT1 (Abcam, ab89901, 1:100),
goat anti-PODXL (R&D systems, BAF1556, 1:200), rabbit anti-CD9 (Abcam,
ab92726, 1:100), rat anti-CD44 (Abcam, ab119348, 1:100), rat anti-CD44 AF647-
conjugated (Biolegend, 103018, 1:100), rabbit anti-integrin ß1 (Abcam, ab179471,
1:500), goat anti-synaptopodin antibody (Santa Cruz Biotechnology; SC21537;
1:400), rabbit anti-p57 antibody (Santa Cruz Biotechnology; SC8298; Santa Cruz;
1:200), goat anti-podoplanin (R&D Systems; AF3244-SP; 1:400), mouse anti-PCNA
(Abcam; ab29; 1:400), and guinea pig anti-synaptopodin (Synaptic Systems;
163004; 1:500).
The following secondary antibodies were used: donkey anti-goat IgG (H+ L)
AF488-conjugated antibody (Life Technologies, A-11005, 1:400), donkey anti-
rabbit IgG (H+ L) AF594-conjugated antibody (A-21207, Life Technologies,
1:400), donkey anti-rat IgG (H+ L) AF488-conjugated antibody (A-21208, Life
Technologies, 1:400), donkey anti-rabbit IgG(H+ L) Cy5-conjugated antibody
(Jackson Immunoresearch, 1:200). The nuclei were stained with DAPI.
Photomicrographs were taken with an Axiophot Zeiss photomicroscope (Jena,
Germany).
For immunohistochemistry, parafﬁn-embedded sections were stained with
primary mouse anti-CD9 antibody for human tissues (kindly provided by Claude
Boucheix and Eric Rubinstein) or rabbit anti-CD9 (Abcam, ab92726, 1:100).
Sections were then incubated with Histoﬁne® (Nichirei Biosciences, Japan) during
2 h at room temperature. Staining was revealed with AEC reagent (DAKO),
counterstained with hematoxylin QS (Vector, Burlingame, CA), and ﬁnalized with
Permanent Aqueous Mounting Media (Innovex).
For quantiﬁcation of histological lesions, an average of 40 glomerular cross-
sections per mice was blindly counted for crescents in NTN model and abnormal
glomeruli, sclerotic lesion above 50% of glomerulus surface and FSGS lesions in the
DOCA-salt model. For red sirius quantiﬁcation, automatic scanning of the whole
kidney section was performed using Vectra technologies. Quantiﬁcation of red
Sirius area was then performed on 13 randomly chosen cortical ﬁelds per mice.
Initially, podocyte number was assessed by the number of WT-1+ cells per
glomerular cross-section in an average of 50 glomerular cross-sections per mice.
Model-based stereology. Podocyte depletion indices were assessed by the Weibel
and Gomez method67 validated by White and Bilous68 in the kidney. This is one of
the preferred methods to determine podocyte depletion parameters when limited
tissue is available69,70. Brieﬂy, 1-μm-thick parafﬁn sections were cut and stained
with anti-p57, anti-SNP, and anti-CD44 antibodies and conjugated with AF488,
AF594, and AF647, respectively. A minimum of ten glomerular cross-sections per
mouse was systematically and randomly selected from the entire renal cortex.
Images were obtained with a confocal laser microscope (LSM 710; Zeiss, Germany)
running the Zen 2009 (Zeiss) software.
In order to estimate glomerular volume, podocyte number and thereby
podocyte density (podocyte number divided by glomerular volume), we
determined the number of podocyte nuclei per glomerular cross-section based on
nuclear p57 and cytoplasmic SNP expression, total area of podocyte nuclei based
on p57 expression, and glomerular tuft area. These parameters were inserted in the
following formulae:
The number of podocytes per glomerulus (Npod) was estimated by:
Npod ¼ Nv ´Gv
NV and Gv represent podocyte density and glomerular volume, respectively.
In order to obtain Nv, we used this equation:
Nv ¼
1
β
 
´ ðNA3  Vv0:5 Þ
NA represents the division of the number of podocyte nuclei by the glomerular
tuft area. VV gives a ratio of total podocyte nuclei area over glomerular tuft area.
The β coefﬁcient of 1.55 was assuming podocyte nuclei are ellipsoids.
Gv was calculated using this equation:
Gv ¼ GA1:5 ´ 1:38 1:01ð Þ
GA represents the glomerular tuft area, 1.38 is the sphere shape coefﬁcient, and
1.01 is the size distribution coefﬁcient that assumes a 10% coefﬁcient of variation.
Furthermore, total podocyte volume was obtained with the same equation:
Pv ¼ PA1:5 ´ 1:38 1:01ð Þ
PV represents total podocyte volume and PA the combination of nuclear (p57+)
and cytoplasmic (SNP+) areas per glomerular cross-section. In order to obtain
average podocyte volume, we divided total podocyte volume by total podocyte
number.
During this process, glomeruli were also categorized based on the presence of
CD44+ PEC, which were identiﬁed based on their anatomical location.
PEC cell line. Primary PEC line has been previously described37 and were a kind
gift from M Moeller. Primary PECs were cultured at 5% CO2, and 37 °C in
complete endothelial cell basal medium (PromoCell) with penicillin/streptomycin
1% (Thermo Fisher Scientiﬁc) and fetal bovine serum (FBS) 20% (Gibco) until 70%
of conﬂuence. The maintenance culture was passaged once a week by gentle
trypsinization by using trysin EDTA 0.05% (Thermo Fisher Scientiﬁc).
Cell silencing of Cd9 by small-hairpin RNA. PECs at passage six were transduced
with a lentivirus encoding for an anti-Cd9 small-hairpin RNA (shRNA) (sh-Cd9)
or a scramble shRNA (sh-scramble) at a dose of 20 multiplicity of infection (MOI).
Medium containing lentiviral particles was replaced by fresh medium after 1 day.
Cells were analyzed at least 7 days post transduction. Production of HIV1 delta U3
SIN lentiviral particles with VSV-G envelop was carried out by the VVTG facility
platform (Necker faculty) by using the lentiviral vector TRC1-pLKO.1-U6- shR
NACd9 (MISSION shRNA, SHCLND NM_007657, TRCN0000066393, Sigma
Aldrich) containing Cd9-speciﬁc shRNA (sequence: CCGGCCTGCAATGAAAGG
TACTATACTCGAGTATAGTACCTTTCATTGCAGGTTTTTG) or the control
vector (MISSION NON-TARGET SHRNA CONTROL VECTOR, SHC002, Sigma
Aldrich).
Cell adhesion assay and cell surface evaluation. In total, 20,000 PEC were plated
in six-well culture plates. Photomicrographs were taken at magniﬁcation ×1000 for
30 min, 1, 6, and 24 h after plating. The number of ﬂoating and adherent cells was
assessed on 15 pictures (average number of cells counted per experiment, n= 460).
Cell surface was evaluated at 24 h of plating on an average number of 100 cells per
condition by using ImageJ software.
Cell migration in IBIDI chambers. Unoriented migration assay was performed
using IBIDI chambers (Culture-Insert 2 Well in µ-Dish 35 mm, high ibiTreat, n°
81176). After conﬂuence was obtained, PECs were grown in ECBM without sup-
plements with FBS 1% overnight. The insert was then removed creating a gap of
500 µm between cells. A ﬁrst round of photographs was taken (H0), shortly after
cells were stimulated with either ECBM without supplements with FBS 1% (con-
trol), or with HB-EGF 10 ng/mL, or with PDGF-BB 10 ng/mL. Photographs were
taken every 30 min for 12 h. Areas of migration were measured by automatic
quantiﬁcation on NIS-Elements AR software.
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Migration in PDGF gradient using microﬂuidic devices. The manufacture of
microchannels has been previously described71. Brieﬂy, we use a soft lithography
technique to obtain a mold with the desired channel architecture. Poly-
dimethylsiloxane (PDMS) is poured over the mold and cured at 70 °C (Fig. 4e).
Afterward, using plasma bonding, the T-shape PDMS microchannel is irreversibly
attached to a glass coverslip. The width of the microchannel is 100 µm.
Parietal epithelial cells are cultured in the ECBM medium, 20% FBS, 1%
penicillin streptomycin) at 37 °C. Channels are treated with plasma cleaner to
render PDMS hydrophilic. FBS is injected into the channel 1 h before cell injection
and incubated at 37 °C. After cells are dissociated with trypsin and resuspended in
culture medium, centrifugation allows a high cell concentration (~107 cells/mL).
Cells are injected into the channel and incubated at 37 °C during 24 h. The day
after, cells are starved using ECBM+ 1% FBS overnight. Cells are used for the
experiment the next day. We typically perform experiments on multiple cells. The
localization of the observed cells in the channel is chosen in order to maximize the
gradient of growth factor. PDGF-BB is used at 20 ng/mL and HBEGF at 20 ng/mL.
Growth factors are diluted in HBSS-HEPES 10 mM. Cells are observed under an
Olympus IX3-CBH microscope using CellSens Dimension software. Figure 5g
shows the geometry of the PDMS microchannel and depicts a typical experiment
under PDGF-BB stimulation. Two syringe pump driven entries are used to supply
liquid ﬂow. Flow rate is 3 µL/min allowing low shear-stress forces inside the
channel, to ensure low Reynold’s number and laminar ﬂow.
Every observable cell was analyzed at the beginning and after 3 h of observation.
Cells were assessed for shape centroid coordinates at both time using ImageJ
software. X axis is oriented in the ﬂow, and Y axis along longitudinal displacement
(i.e. along gradient of concentration). Difference of X and Y coordinates are plotted
on the graphs. For every initial position of cells (Y), the gradient of concentration
could be approximated using the following equation:
C Yð Þ ¼ C0
2
 erfc Yﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2:D:T
p
in which CO is the initial concentration of growth factor (CO= 20 ng/mL for
PDGF-BB and 20 µmol/L for HB-EGF), erfc stands for complementary error
function, Y is the centroid coordinate of the cell in the canal, D is the coefﬁcient of
diffusion of the growth factor and T the time necessary for the ﬂow to reach the X
coordinate of the cell. Only cells exposed to a ΔCC > 100% were taken into account.
This represent the cells localized in the centrum of the microchannel. Absolutes
displacements were evaluated using the difference in X or Y between initial and
ﬁnal position.
Cell-apoptosis assay. Cells viability was assessed using APC conjugated Annexin-
V (ImmunoTools) combined with propidium iodide (PI) (Thermo Fisher Scien-
tiﬁc). Cells were plated in six-well plates during 24 h. Cells were then trypsinized
and washed in cold phosphate-buffered saline (PBS w/o Ca2+). Supernatants were
kept and included in analysis. After centrifugation, cells were then resuspended in
100 µl of Annexin-V binding buffer (BD Pharmingen) and directly stained with
Annexin-V and PI at room temperature for 5 min in the dark. A control tube
without Annexin-V binding buffer was used to sustain aspeciﬁc signal from ﬁnal
analysis. Samples were analyzed on a BD LSRII ﬂow cytometer (BD Bioscience).
The data were analyzed using FlowJo software (FlowJo, LLC). Viable cells were
deﬁned as both Annexin-V and PI negative, apoptotic cells as Annexin-V positive
and PI negative, necrotic cells as both Annexin-V and PI positive, and all popu-
lations were expressed as percentage of total cells.
Proliferation assay. To assess cell proliferation, we used the nuclear antigen
Ki67 staining. After overnight starvation in ECBM+ 1% FBS, cells were treated
24 h with PDGF-BB (10 ng/mL) or HBEGF (20 ng/mL) or corresponding controls.
Cells were then trypsinized and washed in cold PBS. Supernatants were kept and
included in analysis. After centrifugation, cells were permeabilized with 1 mL of ice
cold ethanol for 2 h at −20 °C. Following two washes with FACS buffer (HBSS, 2%
FBS, and 10 mM HEPES), cells were stained for 30 min at room temperature in the
dark with phycoerythrin (PE)-conjugated anti-human Ki67 mAb (clone B56) (BD
Pharmingen) and washed. Samples were analyzed on a BD LSRII ﬂow cytometer
(BD Bioscience). An isotype control staining with PE mouse IgG1 was performed.
The data were analyzed using FlowJo software (FlowJo, LLC).
Western blot analysis. PEC lysates were prepared with RIPA extraction buffer
containing phosphatase inhibitors and protease inhibitors (Roche). Equal amounts
of proteins were loaded onto sodium dodecyl sulfate–polyacrylamide electro-
phoresis gels for separation and transferred onto poly(vinylidene diﬂuoride)
membranes. The membranes were blocked with milk and probed with different
antibodies: rat anti-CD9 (BD Pharmingen, 553758, 1:1000), rabbit anti-phospho-
PDGF receptor-ß Y1009 (Cell Signaling Technology, 4549; 1:1000), rabbit anti-
PDGFRβ (Cell Signaling, 3169; 1:1000), rabbit anti-integrin ß1 (Millipore, 04-1109,
1:1000), rabbit anti-CASP3 (Cell Signaling Technology, 9662; 1:1000), rabbit anti-
phospho EGFR Y1068 (Cell Signaling Technology, 2234; 1:1000), rabbit anti EGFR
(Cell Signaling Technology, 2232; 1:1000), rabbit anti-phospho-FAK Y397 (Cell
Signaling 3283, 1:1000), rabbit anti-FAK (Millipore, 06-543, 1:1000). Membranes
were then probed with horseradish peroxidase-conjugated secondary antibodies
(Cell Signaling Technology, 7074 and 7076; 1:2000; Jackson Immunoresearch, 706-
036-148; 1:1000) and bands were visualized by enhanced chemiluminescence
(Clarity Western ECL substrate; Bio-Rad, 170–5061). A LAS-4000 imaging system
(Fuji, LAS4000, Burlington, NJ, USA) was used to reveal bands and densitometric
analysis was used for quantiﬁcation. Uncropped blots are shown in Supplementary
Figs 18–22.
Quantitative RT-PCR. The total RNA extraction of mouse glomeruli and lung
tissue was performed using Qiazol (Qiagen), according to the manufacturer’s
recommendations. RNA reverse transcription was performed using the Quantitect
Reverse Transcription kit (Qiagen) according to the manufacturer’s protocol. The
Maxima SYBR Green/Rox qPCR mix (Fermentas; Thermo Fisher Scientiﬁc) was
used to amplify cDNA for 40 cycles on an ABI PRISM thermo cycler. The com-
parative method of relative quantiﬁcation (2-DDCT) was used to calculate the
expression level of each target gene, normalized to Ppia. The data are presented as
the fold change in gene expression.
The oligonucleotide sequences are available on the Supplementary Information
as Supplementary Table 3.
Statistical analysis. Data are expressed as means ± s.e.m. Statistical analyses were
calculated by using GraphPad Prism software (GraphPad Software, La Jolla, CA).
Comparisons between two groups were performed using t tests (95% conﬁdence
interval) with Welch correction whenever the variances were different between
groups. Comparisons between multiple groups were performed using one-way
ANOVA or two-ways ANOVA followed by Tukey post-test. Spearman rank
coefﬁcients were used in order to assess associations between two continuous
variables. A P-value < 0.05 was considered signiﬁcant.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors declare that the data supporting the ﬁndings of this study are available
within the paper and its supplementary information ﬁles. Source data for Figs 1b, 2a, b,
3a, b, d, 4c, d, g–i, 5a b, d, h, i, and 6b, e–k and supplementary ﬁgures are provided as a
Source Data ﬁle. All data are available from the corresponding authors upon reasonable
request. A reporting summary for this article is available as a Supplementary
Information ﬁle.
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